NCT06532279 2026-04-03
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NRG Oncology
Thomas Jefferson University
Roswell Park Cancer Institute
Thomas Jefferson University
Ohio State University Comprehensive Cancer Center